Among the remaining cancer subtypes, we noticed exclusively decreased immune cell populations in the TP53mut tumors of six subtypes, a mixed pattern of increased and decreased immune cell populations in four subtypes (HR+/HER2- BRCA, HER2+ BRCA, LGG, and LUAD), and exclusively increased immune cell populations in BLCA and PRAD. This evidence concerns the gene ERBB2 and prostate adenocarcinoma.